29 related articles for article (PubMed ID: 34620629)
1. Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea.
Joung KI; Hwang JE; Oh IS; Cho SI; Shin JY
Sci Rep; 2022 Dec; 12(1):22396. PubMed ID: 36575247
[TBL] [Abstract][Full Text] [Related]
2. Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer.
Kang H; Nam CM; Choi DW; Park S
Front Oncol; 2023; 13():1182174. PubMed ID: 37576886
[TBL] [Abstract][Full Text] [Related]
3. A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Hedenmalm K; Quinten C; Kurz X; Bradley M; Lee H; Eworuke E
Eur J Clin Pharmacol; 2023 Jun; 79(6):849-858. PubMed ID: 37095262
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment of
; Schrenk D; Bignami M; Bodin L; Chipman JK; Del Mazo J; Hogstrand C; Ron Hoogenboom L; Leblanc JC; Nebbia CS; Nielsen E; Ntzani E; Petersen A; Sand S; Schwerdtle T; Vleminckx C; Wallace H; Romualdo B; Cristina F; Stephen H; Marco I; Mosbach-Schulz O; Riolo F; Christodoulidou A; Grasl-Kraupp B
EFSA J; 2023 Mar; 21(3):e07884. PubMed ID: 36999063
[TBL] [Abstract][Full Text] [Related]
5. Possible Association between the Use of Proton Pump Inhibitors and H
Choi HG; Lee HK; Kang HS; Lim H; Kim JH; Kim JH; Kim NY; Cho SJ; Nam ES; Min KW; Kwon MJ
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631344
[TBL] [Abstract][Full Text] [Related]
6. Hypersensitivity reaction to ranitidine: description of a case and review of the literature.
Foti C; Cassano N; Panebianco R; Calogiuri GF; Vena GA
Immunopharmacol Immunotoxicol; 2009; 31(3):414-6. PubMed ID: 19694603
[TBL] [Abstract][Full Text] [Related]
7. How often we diagnose allergy to ranitidine?
Bocșan IC; Sabin O; Matei D; Muntean A; Buzoianu AD
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10812-10818. PubMed ID: 33155242
[TBL] [Abstract][Full Text] [Related]
8. Ranitidine Use and Risk of Upper Gastrointestinal Cancers.
Adami HO; Trolle Andersen I; Heide-Jørgensen U; Chang ET; Nørgaard M; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2302-2308. PubMed ID: 34620629
[TBL] [Abstract][Full Text] [Related]
9. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
10. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.
Iwagami M; Kumazawa R; Miyamoto Y; Ito Y; Ishimaru M; Morita K; Hamada S; Tamiya N; Yasunaga H
Drug Saf; 2021 Mar; 44(3):361-371. PubMed ID: 33247391
[TBL] [Abstract][Full Text] [Related]
11. Prescription changes in patients with gastrointestinal disorders after withdrawal of ranitidine: a nationwide population-based cohort study.
Ku M; Je NK
Curr Med Res Opin; 2023 Feb; 39(2):197-203. PubMed ID: 36519289
[TBL] [Abstract][Full Text] [Related]
12. Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.
Cardwell CR; McDowell RD; Hughes CM; Hicks B; Murchie P
Am J Gastroenterol; 2021 Aug; 116(8):1612-1619. PubMed ID: 34028367
[TBL] [Abstract][Full Text] [Related]
13. The Association between Ranitidine Use and Gastrointestinal Cancers.
McGwin G
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374592
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
